C1q Binding Ability for Prior Risk Assessment of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.

Autor:	Miwa Y; Department of Kidney Disease and Transplant Immunology, Aichi Medical University School of Medicine, Nagakute, Japan., Iwasaki K; Department of Kidney Disease and Transplant Immunology, Aichi Medical University School of Medicine, Nagakute, Japan., Murotani K; Biostatistics Center, Kurume University, Kurume, Japan., Okada M; Department of Transplant Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan., Nagasaka T; Department of Transplant Surgery, Toyohashi Municipal Hospital, Toyohashi, Japan., Watarai Y; Department of Transplant Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan., Takeda A; Department of Nephrology, Masuko Memorial Hospital, Nagoya, Japan., Shizuku M; Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan., Ashimine S; Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan., Ishiyama K; Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan., Maruyama S; Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Kobayashi T; Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan.
Jazyk:	angličtina
Zdroj:	Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2024 Oct 15; Vol. 37, pp. 13407. Date of Electronic Publication: 2024 Oct 15 (Print Publication: 2024).
DOI:	10.3389/ti.2024.13407
Abstrakt:	In ABO blood group incompatible kidney transplantation (ABO-I), potential issues on acute antibody-mediated rejection (ABMR) remain to be solved. This study aimed to assess the risk factors of acute ABMR using recipient- or donor-derived specimens. Quantitative analysis of A/B antigen expression was conducted in 104 donor kidney tissues (Kt), platelets (Plt), and red blood cells (RBC) by immunohistochemical staining or flow cytometry (FCM). ABO-I pre-transplant recipient serum samples (ABMR = 12, non-ABMR = 27) were extracted by propensity score matching. Anti-A antibody titers of IgM, IgG and IgG subclasses, and C1q binding ability (%) on antibody were measured using RBC-FCM. No association was observed between ABMR and A/B antigen expression levels in donor's Plt, RBC, or Kt. In recipient's sample, C1q-IgG binding ability was significantly higher in the ABMR group than in the non-ABMR group (C1q-IgG: 9.04% vs. 5.93% p = 0.049). Neither the A/B antigen expression level in donors (grafts) nor anti-blood group IgG/IgM antibodies in recipient sera before desensitization seemed to influence ABMR incidence in ABO-I. In contrast, C1q-IgG binding ability could be a potential predictor for ABMR in ABO-I. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Miwa, Iwasaki, Murotani, Okada, Nagasaka, Watarai, Takeda, Shizuku, Ashimine, Ishiyama, Maruyama and Kobayashi.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu